Dermatology Clinical Research
Visual endpoints. Patient experience. Real-world rigour.
Dermatology trials sit at the intersection of clinical efficacy, visual assessment, and patient-reported outcomes. Whether measuring lesion reduction, clearance rates, or quality-of-life improvements, the data depends on consistent evaluation methodologies and engaged participants both of which demand a team that understands the nuance of skin-related indications.
At Southern Star Research, we support dermatology clinical trials with a hands-on, patient-focused approach. Our teams understand the realities of outpatient delivery, the discipline required for visual endpoint consistency, and the importance of keeping participants engaged across study visits.
Indication experience
This spans Phase 1 and Phase 2, and includes both interventional and non-interventional designs.
Why Australia for dermatology clinical trials?
Australia offers experienced dermatology investigators, diverse outpatient populations, and strong clinical governance – producing high-quality data accepted by the FDA, EMA, and other major regulators. Study start-up is efficient, and participant follow-up is reliable.
For sponsors evaluating dermatology research in APAC, Australia provides a proven regulatory environment without the complexity of navigating multiple country-specific frameworks from the outset.